<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/nektar-therapeutics-logo-1200x675.png/query-dj0yMDIyMTIwOTExNDE1Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/nektar-therapeutics-logo-1200x675.png/query-dj0yMDIyMTIwOTExNDE1Mw"/>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) insider Mark Andrew Wilson sold 676 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $26.59, for a total value of $17,974.84. Following the sale, the insider owned 20,312 shares in the company, valued at $540,096.08. The trade was a 3.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.</p><h2>Nektar Therapeutics Stock Performance</h2><ul><li>3 Bullish Biotech Stocks With Explosive Growth Trends</li></ul><p>Shares of NKTR stock opened at $28.00 on Friday. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $37.38. The firm has a market capitalization of $532.56 million, a price-to-earnings ratio of -3.18 and a beta of 0.95. The stock's 50-day simple moving average is $22.50 and its 200-day simple moving average is $14.96. </p><p>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) EPS for the quarter, topping analysts' consensus estimates of ($3.13) by $0.18. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%.The firm had revenue of $11.18 million during the quarter, compared to the consensus estimate of $9.42 million.  As a group, equities analysts forecast that  Nektar Therapeutics will post -0.72 earnings per share for the current year. </p><h2>Hedge Funds Weigh In On Nektar Therapeutics</h2><hr/><hr/><br/><ul><li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li></ul><p>Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase &amp; Co. raised its position in  Nektar Therapeutics by 29.5% in the 4th quarter. JPMorgan Chase &amp; Co. now owns 1,182,995 shares of the biopharmaceutical company's stock valued at $1,100,000 after purchasing an additional 269,695 shares in the last quarter.  Wells Fargo &amp; Company MN increased its holdings in shares of  Nektar Therapeutics by 26.5% in the 4th quarter. Wells Fargo &amp; Company MN now owns 108,975 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 22,822 shares during the last quarter.  Renaissance Technologies LLC grew its stake in  Nektar Therapeutics by 17.5% during the 4th quarter. Renaissance Technologies LLC now owns 3,910,786 shares of the biopharmaceutical company's stock worth $3,637,000 after buying an additional 583,153 shares during the last quarter.  XTX Topco Ltd grew its stake in  Nektar Therapeutics by 595.8% during the 4th quarter. XTX Topco Ltd now owns 244,701 shares of the biopharmaceutical company's stock worth $228,000 after buying an additional 209,531 shares during the last quarter.  Finally, Harvest Investment Services LLC acquired a new stake in  Nektar Therapeutics during the 4th quarter worth approximately $27,000. Institutional investors and hedge funds own  75.88% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of research analysts have issued reports on the company. BTIG Research boosted their price target on Nektar Therapeutics from $60.00 to $100.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, June 24th. B. Riley boosted their price target on Nektar Therapeutics from $60.00 to $85.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 8th. William Blair  reissued a &#34;market perform&#34; rating on shares of Nektar Therapeutics in a report on Monday, May 12th. HC Wainwright boosted their price objective on Nektar Therapeutics to $120.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, June 24th. Finally, Wall Street Zen cut Nektar Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one  has assigned  a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $88.33.</p><ul><li>Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?</li></ul><p><b>Check Out Our Latest Analysis on NKTR</b></p><h2>About Nektar Therapeutics</h2><p> (Get Free Report)</p><p>Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Nektar Therapeutics</li><li>Short Selling - The Pros and Cons </li><li>Can Identity Security Fuel CrowdStrike’s Next Growth Phase?</li><li>What Are Dividend Achievers? An Introduction</li><li>Broadcom Named in Apple’s $100B U.S. Investment Plan</li><li>Why Are These Companies Considered Blue Chips?</li><li>3 Reasons Salesforce Is a Bargain Right Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Nektar Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Nektar Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250811113850_pushainewer-11.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250811113850_pushainewer-11.jpg"/></p><div><p>One tiny company just cracked Google’s $19B problem</p><p>Google’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...</p><p><span>True Market Insiders</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUyOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUyOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg"/></p><div><p>[No Brainer Gold Play]: “Show me a better investment.”</p><p>A Historic Gold Announcement Is About to Rock Wall Street?  For months, sharp-eyed analysts have watched the...</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDM3MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDM3MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250815152843_pushsir-eai-6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="112" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250815152843_pushsir-eai-6.jpg"/></p><div><p>US attacks China, September 30?</p><p>The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYxNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDYxNQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20250807152845_unnamed.png/query-MTc1NDU5ODUyNTgyMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="312" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20250807152845_unnamed.png/query-MTc1NDU5ODUyNTgyMA"/></p><div><p>I trusted Trump and got screwed</p><p>Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDQ5Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDQ5Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2067push_AI-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2067push_AI-9.jpg"/></p><div><p>Everyone’s watching Nvidia right now. Here’s why I’m excited.</p><p>So, unless you’ve been living under a rock, you probably saw the news…  Nvidia just signed a $7 BILLION deal...</p><p><span>Timothy Sykes</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDM1NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDM1NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250807142608_pushlightbulb-5352822640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250807142608_pushlightbulb-5352822640.jpg"/></p><div><p>But this $20 American company could control the secret</p><p>The &#34;Impossible&#34; Chip That Runs on Pure Light  Google's quantum computer shocked the world... but China DEMO...</p><p><span>The Oxford Club</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDQ4Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDQ4Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113206_pushblur-1853262640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250812113206_pushblur-1853262640.jpg"/></p><div><p>Generate up to $5,000/month with 10X less money?</p><p>The secret to retiring without a million-dollar nest egg.   I'm talking about generating enough monthly inco...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUzOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUzOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://finance.weissratings.com/media/images/blasts/2025/rpl/RPL050625_D01_KV.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="332" height="373" original-src="https://imageproxy.pbkrs.com/https://finance.weissratings.com/media/images/blasts/2025/rpl/RPL050625_D01_KV.jpg"/></p><div><p>Take a look at this picture ...</p><p>A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...</p><p><span>Weiss Ratings</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUxMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDUxMQ"/></p></div></div></div>                     </div>                 </div></div>

NKTR

<p>Nektar Therapeutics insider Mark Andrew Wilson sold 676 shares at $26.59 each, totaling $17,974.84, resulting in a 3.22% decrease in his ownership. Post-sale, he holds 20,312 shares valued at $540,096.08. The transaction was disclosed to the SEC. Nektar's stock opened at $28.00, with a market cap of $532.56 million and a P/E ratio of -3.18. The company reported a quarterly EPS of ($2.95), exceeding estimates, and had revenue of $11.18 million. Analysts have set a moderate buy rating with an average target price of $88.33.</p>

Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 676 Shares